Loratadine Link To Birth Defect Discounted In CDC Report
This article was originally published in The Tan Sheet
An analysis of data from the ongoing National Birth Defects Prevention Study found no association between loratadine and second- or third-degree hypospadias, according to the Centers for Disease Control & Prevention's March 19 Morbidity & Mortality Weekly Report
You may also be interested in...
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning